Sponsors (6)
The bill boosts NATO and allied biodefense coordination, safety standards, and export controls to strengthen preparedness against biological threats, while imposing higher compliance and defense costs and creating potential gaps from a narrow legal scope and reduced transparency.
Federal agencies, NATO members, and state governments will coordinate to strengthen NATO biodefense planning, improving collective detection, response, and interoperability for biological threats.
Scientists, federal export authorities, and allied partners will coordinate export controls on dual-use biotechnology items, reducing the risk that materials enabling biological weapons reach hostile actors.
Scientists, researchers, and health systems among U.S. allies will face stronger safety and security standards for biological research, lowering the risk of accidental or intentional pathogen release.
Scientists, researchers, hospitals, and biotech firms will face stronger export controls and research restrictions that could slow international scientific collaboration and raise compliance costs.
Taxpayers and military personnel may bear increased costs because expanding NATO biodefense roles and R&D cooperation can raise U.S. defense commitments and spending for capability development and deployments.
Federal agencies and military planners could be left exposed because the bill’s narrow statutory focus on agents defined in 18 U.S.C. §178 may exclude emerging biological threats or novel modalities.
Based on analysis of 2 sections of legislative text.
Directs the State Department to lead diplomatic efforts with NATO and allies to strengthen biodefense, develop a NATO Biodefense Strategy, and improve interoperability, R&D, and biosafety norms.
Introduced February 23, 2026 by Keith Self · Last progress February 23, 2026
Requires the State Department to lead diplomatic efforts with NATO and other U.S. allies and partners to strengthen international cooperation on biodefense, biosecurity, and biotechnology. It directs senior State Department officials, in coordination with the U.S. Permanent Representative to NATO, to push NATO to prioritize biotechnology and biodefense policy, improve planning and interoperability, update CBRN policy for biodefense, promote high safety and security standards in biological research, and explore allied R&D and deployment opportunities. Also directs the State Department to develop a named “NATO Biodefense Strategy” that assesses U.S.–NATO cooperation, identifies gaps in NATO biotechnology and biodefense capabilities and planning, and recommends ways to close those gaps; the text indicates a second required strategy but is incomplete in the provided excerpt. The measure sets responsibilities and coordination roles but does not specify new funding or implementation timing.